Genetically guided (GG) selection of P2Y12 inhibitor after percutaneous coronary intervention (PCI) should be used routinely to reduce ischemic events, say researchers as a new analysis of data from the TAILOR-PCI trial shows 40% reduction in cumulative ischemic events per patient.